The global Manufacturing Execution System (MES) Providers in Healthcare Market Size is valued at 3.4 Billion in 2023 and is predicted to reach 14.55 Billion by the year 2031 at a 14.55 % CAGR during the forecast period for 2024-2031.
Manufacturing execution systems (MES) are computerized systems that track and document the transformation of raw materials to finished commodities in manufacturing. MES delivers information that assists manufacturing decision-makers in understanding the plant floor conditions to increase production output. Biotech, pharmaceutical, and medical device companies must have accurate information from their supply chain, verify that the equipment on the factory floor is operational, and adhere to tight quality control standards and laws. They assist pharmaceutical businesses in developing faultless production processes that decrease risks, time, costs, and effort while increasing process efficiency and product quality. Several healthcare stakeholders have taken active steps to integrate a manufacturing execution system into their production lines to connect, monitor, and control the complicated manufacturing process. It has also been observed that enterprises are increasingly embracing cloud-based manufacturing execution systems to solve the issues associated with increased process complexity and worldwide business expansion.
The need for mass production and a connected supply chain to serve a growing population, rapid advancements in infrastructure and manufacturing equipment, and improved innovations in medical care will all contribute to an increase in the demand for MES and other management systems to meet the demands of production across the world. This increase in demand for MES and other management systems is expected to take place in the next few years. In addition, cloud computing will be one of the growth drivers of MES usage, along with digital transformation, IIoT, and additional integrated ways to leverage connected data, including advanced data and analytics platforms, as certain industries adopt cloud MES more quickly. In February 2021, Atachi Systems promised the first fifty small pharmaceutical, medical device, and diagnostics firms that they would provide free MES software for one year. To tackle against the Coronavirus, it is necessary to speed up the development and commercialization of antiviral drugs, diagnostic instruments, and medical technology.
The worldwide industry may be hampered by the requirement of considerable capital expenditures for the deployment, upgrade, and maintenance of MES. The market expansion will be slowed down as a result of the willingness of smaller healthcare firms to secure appropriate funding for technological upgrades toward automation.
Market Segmentation
The Manufacturing Execution System (MES) Providers in Healthcare market is segmented into deployments and end-user. The deployment segment comprises Cloud Solutions, Corporate Datacenter Solutions, Hybrid Solutions, and On-Premise Solutions. The end-user segment includes Life science / Biotechnology Companies, Medical Device Providers, Pharmaceutical Companies, and Other End-users.
According to regional analysis, Europe will lead the global Manufacturing Execution System (MES) Providers in Healthcare market during the forecast period due to rapid technical breakthroughs and system upgrades based on automation and manufacturing industry improvements.
Competitive Landscape
Some major key players in the Manufacturing Execution System (MES) Providers in Healthcare Market:
- Andea,
- Critical Manufacturing,
- Dassault Systèmes,
- GE Digital, Infor,
- Körber,
- LZ Lifescience Inc.,
- Rockwell Automation,
- Honeywell,
- Trunovate,
- NoMuda,
- HCL Technologies Limited,
- ORDINAL Software,
- Atachi Systems,
- ATS Global,
- MasterControl, Inc.,
- NNIT,
- Aspen Technology Inc,
- Goodly-Innovations GmbH,
- ADVANCO SA,
- Enhanced Information Solution,
- POMS Corporation,
- Tulip,
- Siemens,
- GFOS,
- znt-Richter
Manufacturing Execution System (MES) Providers in Healthcare Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.4 Billion |
|
Revenue Forecast In 2031 |
USD 9.68 Billion |
|
Growth Rate CAGR |
CAGR of 14.55% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Deployment, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Andea, Critical Manufacturing, Dassault Systèmes, GE Digital, Infor, Körber, LZ Lifescience Inc., Rockwell Automation, Honeywell, Trunovate, NoMuda, HCL Technologies Limited, ORDINAL Software, Atachi Systems, ATS Global, MasterControl, Inc., NNIT, Aspen Technology Inc, Goodly-Innovations GmbH, ADVANCO SA, Enhanced Information Solution, POMS Corporation, Tulip, Siemens, GFOS, znt-Richter, Other Prominent Players.Alkahest, Inc., Stealth BioTherapeutics, BIOPHYTIS BSA, SIWA Therapeutics, Rejuveron Life Sciences AG, Rubedo Life Sciences, Inc, Lineage Cell Therapeutics, Juvenescence Life, Longevity Biotech CohBar, Inc. (CWBR), Genome Protection Inc., Navitor Pharmaceuticals, Inc., Elevian, Inc., Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
